Navigation Links
PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
Date:9/2/2008

BOSTON, Sept. 2 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Thomas Weisel Partners Healthcare Conference in Boston, MA. Josef von Rickenbach, Chairman and Chief Executive Officer will be making a formal presentation on PAREXEL at 3:50 p.m. EDT on Thursday, September 4, 2008.

A live webcast of this presentation will be available under the "Upcoming Events" section on PAREXEL's "Investors" homepage at http://www.PAREXEL.com. A replay of the presentation will be available until October 4, 2008.

About the Company

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has over 8,800 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

PAREXEL is a registered trademark of PA
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...HOUSTON, Dec. 3 JourneyLite of Ho...s facility to offer patients a second surgical opt... LAP-BAND® System that it currently perform...acility was performed by surgeon partner, Matthew... is reported as doing well. ,, The Vertical Sle...
(Date:12/3/2009)...ILLE, N.Y., Dec. 3 Nikon Corporati...announced today that it has signed a licensing agr...rights to use the Stochastic Optical Reconstructio...f the agreement, Nikon will manufacture STORM enab...STORM name. ,, Nikon Corporation President, Mr...
(Date:12/3/2009)... DALLAS, Dec. 3 ACCESS...CP), today provided an update on its European comm... for oral mucositis, a debilitating side effect of...ommercially launched by Access, partner, SpePharm,...any, Italy, Norway, Greece and Sweden. Access is c...
(Date:12/3/2009)...FRANCISCO, Dec. 3 VIA Ph...ogy company focused on the development of compound...c disease, today announced that it has completed t...cal trial of VIA-2291. ,, The FDG-PET trial en...es in the US and Canada including Massachusetts Ge...
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
...TH SAN FRANCISCO, Calif., June 3 Exelixis,Inc. (N...gos, PhD, president,and chief executive officer of...Annual Global Healthcare Conference at 11:00 a.m. ...ngos will discuss updates to the company,s,develop...tation will be webcast and may be accessed in the ...
...COUVER, June 3 /PRNewswire-FirstCall/ - Angiotech ... global specialty pharmaceutical and,medical devic...clinical,trial enrolment for its novel Bio-Seal lu...product represents a potentially significant,impro...cer," said Dr.,William Hunter, President and CEO o...
...XANDRIA. Va., June 3 Oxford Finance Corporation a...provided a $7.5 million,senior secured loan to Axo... company., AxoGen is a leader in the advancement ..., AVANCE(TM) Nerve Graft is a biological solution ...f peripheral nerves., "Oxford,s and ATEL,s suppor...
Other Biology Technology:Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 2Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 3Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment 4Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc. 2
(Date:12/3/2009)...s co-workers discovered that specific types of hum...entists soon found out how these pathogens cause c...n culprits are viral proteins E6 and E7. Both prot...ns, thus promoting cell growth. , Professor Dr....covered another mechanism by which the E6 oncoprot...
(Date:12/3/2009)...liminary Press Conference Topics, Last Call! Pre...seum, Attention PIOs: Sending Press Releases to ... deadline 10 December, News Media registration i...gistration deadline THIS MONDAY, 7 December, Who...ing visas for international reporters, please see:...
(Date:12/3/2009)...ity change in warmer water, according to an intrig...make some species more aggressive. , Experiments...,s Great Barrier Reef have shown for the first tim...d, or consistently bold, and that these individual...tures rise. , A slight lift of just one or two d...
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Fish with attitude: Some like it hot 2Is it Exam Time for Georgias School Children Already 3F 53843 1Is it Exam Time for Georgias School Children Already 3F 53843 2Is it Exam Time for Georgias School Children Already 3F 53843 3Is it Exam Time for Georgias School Children Already 3F 53843 4CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 53841 1CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 53841 2Transcept Pharmaceuticals to Report Second Quarter 2009 Results 53839 1Transcept Pharmaceuticals to Report Second Quarter 2009 Results 53839 2Transcept Pharmaceuticals to Report Second Quarter 2009 Results 53839 3Transcept Pharmaceuticals to Report Second Quarter 2009 Results 53839 4
...from the Universities of Geneva and Lausanne, as w...been part of a major international project to sequ...w named L1 Dominette. Sequencing the bovine genome... more sustainable food production, taking into acc...The genome provides a major novel resource to stud...
...have developed a breakthrough method for sequencin...el personalized regenerative medicine and even lea... studying certain diseases. , To do this, the re...essor in the UC San Diego Jacobs School of Enginee...g DNA methylation digitally on an arbitrary set of...
...n to patients with vertebral compression fractures...hlgrenska Academy, University of Gothenburg, Swede...severe pain one year after the fracture. , Verte...ogether of a vertebra in the spine such that its h...suffer from vertebral compression fractures in Swe...
Other Biology News:Sequencing the cow's genetic code -- a new agricultural era dawns 2New method developed by UC San Diego bioengineers gives regenerative medicine a boost 2New method developed by UC San Diego bioengineers gives regenerative medicine a boost 3Poor treatment for common vertebral compression fractures 2
Scaffold Software from Proteome Software Inc.
Normal Goat Serum from Calbiochem
TRIzol LS Reagent from Invitrogen
UltraPure DNase/RNase-Free Distilled Water from Invitrogen
Biology Products: